Objective
to compare next-generation cobalt-chromium based TiNO coated stents with platinum-chromium based biodegradable polymer everolimus-eluting stents (EES)
Study
multicentre, randomised trial (2:1)
Population
patients with ACS (acute coronary syndrome)
Endpoints
composite of cardiac death, MI or ischaemia-driven target lesion revascularisation at 12 months. Co-primary endpoint: composite cardiac death, MI or major bleeding at 18 months


Conclusion
in patients with ACS TiNO coated stents were not different to EES stents for major cardiac events at 12 months, but were better for co-primary endpoint (cardiac death, MI and major bleeding) at 18 months
Tonino et al. J Am Coll Cardiol Intv. 2020;13:1697-705